Mannkind News (NASDAQ:MNKD)
| Latest Mannkind News Headlines | | Date | Time | Source | | | 06/24/2008 | 10:00AM | PRNUS | BeaconEquity.com Issues TraderNotes on Active Stocks: NLN, GRVY, MDTL, ENER, BTRX, MNKD, ALTI, BG
DALLAS, June 24 /PRNewswire/ -- BeaconEquity.com announces the availability of TraderNotes on stocks that are making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/
Today's TraderNotes include: National Lampoon Incorporated (AMEX:NLN), Gravity Co. Ltd... More...>> |
| 06/16/2008 | 5:02PM | PRNUS | MannKind to Present at Upcoming Conferences
VALENCIA, Calif., June 16 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences.
-- 18th Annual Wachovia Nantucket Equity Conference on Monday, June 23... More...>> |
| 05/07/2008 | 5:00PM | PRNUS | MannKind to Present at Upcoming Conferences
VALENCIA, Calif., May 7 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences.
-- Bank of America Health Care Conference on Wednesday, May 14, 2008 at... More...>> |
| 05/05/2008 | 4:00PM | PRNUS | MannKind Corporation Reports First Quarter Financial Results
- Conference Call Today at 5:00 p.m. EDT -
VALENCIA, Calif., May 5 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the first quarter ended March 31, 2008.
For the first quarter of 2008, total operating expenses were $74.1 million, compared to $77.3 million for the first... More...>> |
| 05/05/2008 | 2:08PM | PRNUS | The Leukemia & Lymphoma Society and MannKind Corporation Announce Collaborative Research Agreement
New Partnership under LLS's Therapy Acceleration Program to Advance Development of a Novel Targeted Therapy for T-Cell Leukemia and Lymphoma
WHITE PLAINS, N.Y. and VALENCIA, Calif., May 5 /PRNewswire-FirstCall/ -- The Leukemia & Lymphoma Society (LLS) and MannKind Corporation, (MNKD), today jointly announced the execution... More...>> |
| 04/28/2008 | 5:00PM | PRNUS | MannKind to Present at the Morgan Stanley Healthcare Conference
VALENCIA, Calif., April 28 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Morgan Stanley Healthcare Conference on Wednesday, April 30, 2008 at 8:30 AM ET at The Ritz-Carlton... More...>> |
| 04/28/2008 | 5:00PM | PRNUS | MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
VALENCIA, Calif., April 28 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) will release its 2008 first quarter financial results on Monday, May 5, 2008 at 4:00 p.m. EDT.
Management of the Company will host a conference call to discuss the first quarter financial results, clinical progress and other Company... More...>> |
| 04/16/2008 | 5:31PM | PRNUS | Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
VALENCIA, Calif., April 16 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) today announced that Matthew J. Pfeffer will join the company as Corporate Vice President and Chief Financial Officer, effective April 21, 2008. Mr. Pfeffer will report to Hakan Edstrom, President and Chief Operating Officer, and... More...>> |
| 04/10/2008 | 9:00AM | PRNUS | MannKind Addresses Pfizer's Announcement Regarding Exubera
VALENCIA, Calif., April 10 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) released the following statement in response to the announcement by Pfizer Inc. that over the course of Exubera's clinical trial program, 6 of the 4,740 patients treated with Exubera developed lung cancer, although Pfizer concluded... More...>> |
| 03/13/2008 | 7:45PM | PRNUS | MannKind to Present at the Cowen and Company Healthcare Conference
VALENCIA, Calif., March 13 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Cowen and Company Healthcare Conference on March 17, 2008 at 3:15 PM ET at the Marriott Copley... More...>> |
| 03/10/2008 | 1:51PM | PRNUS | MannKind Corporation Response to Recent Market Events
VALENCIA, Calif., March 10 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) today issued the following statement in response to recent market events:
MannKind is absolutely committed to the continued development of its lead development product, Technosphere(R) Insulin. We use our small, patient-friendly... More...>> |
| 03/04/2008 | 7:00AM | PRNUS | MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results
- Conference Call to Begin Today at 9:00 a.m. ET -
VALENCIA, Calif., March 4 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the fourth quarter and year ended December 31, 2007.
For the fourth quarter of 2007, total operating expenses were $79.1 million, compared to... More...>> |
| 02/28/2008 | 8:45PM | PRNUS | MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
VALENCIA, Calif., Feb. 28 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) will release its 2007 fourth quarter financial results on Tuesday, March 4, 2008 at 7:00 a.m. ET.
Management of the Company will host a conference call to discuss the fourth quarter financial results, clinical progress and other... More...>> |
| 02/01/2008 | 5:45PM | PRNUS | MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
VALENCIA, Calif., Feb. 1 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 6, 2008... More...>> |
| 01/25/2008 | 4:30PM | PRNUS | MannKind to Present at the Wachovia 2008 Healthcare Conference
VALENCIA, Calif., Jan. 25 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Wachovia Healthcare Conference on January 30, 2008 at 2:00 PM ET at the Langham Hotel in Boston... More...>> |
| 01/07/2008 | 9:00AM | PRNUS | John R. Riesenberger Joins MannKind as Corporate Vice President and Chief Commercialization Officer
VALENCIA, Calif., Jan. 7 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD), today announced that John Riesenberger has joined the company as Corporate Vice President and Chief Commercialization Officer. Mr. Riesenberger will report to Hakan Edstrom, President and Chief Operating Officer, and serve on MannKind's... More...>> |
| 01/02/2008 | 9:00AM | PRNUS | MannKind to Present at the JP Morgan Healthcare Conference
VALENCIA, Calif., Jan. 2 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the JP Morgan Healthcare Conference on January 8, 2008 at 8:00 a.m. Pacific Time at the Westin St... More...>> |
| 11/20/2007 | 5:45PM | PRNUS | MannKind to Present at the Piper Jaffray Healthcare Conference
VALENCIA, Calif., Nov. 20 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Piper Jaffray Healthcare Conference on November 27, 2007 at 10:30 AM ET at the Pierre Hotel in... More...>> |
| 11/07/2007 | 6:00AM | PRNUS | MannKind Corporation Reports Third Quarter Financial Results
- Conference Call Today at 8:00 a.m. ET -
VALENCIA, Calif., Nov. 7 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the third quarter ended September 30, 2007.
For the third quarter of 2007, total operating expenses were $75.6 million, compared to $61.1 million for the... More...>> |
| 11/05/2007 | 8:00AM | PRNUS | MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
VALENCIA, Calif., Nov. 5 /PRNewswire-FirstCall/ -- MannKind Corporation (NASDAQ:MNKD) today announced results from a Phase 1a clinical evaluation of MKC253, a formulation of GLP-1 (glucagon-like peptide) on Technosphere particles that is delivered using the Company's proprietary inhaler. The study was designed as an... More...>> |
|
|
|